Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.

MDMA-assisted psychotherapy for PTSD shows promise in clinical trials, with the FDA granting breakthrough therapy designation based on earlier results. The treatment combines MDMA's pharmacological effects—enhancing fear extinction, increasing oxytocin and trust, and reducing amygdala reactivity—with specific psychotherapeutic methods. If ongoing phase 3 trials meet efficacy criteria, FDA approval could come as early as 2022. The article reviews mechanisms of action, therapeutic rationale, and potential dangers of this approach, which revisits a previously banned psychoactive substance to address the limited effectiveness of current PTSD treatments.

Study at a glance

Abstract

Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended various therapeutic approaches, including both pharmacotherapy and psychotherapy, treatment is not as effective as expected. Over recent years the pharmaceutical industry has not been able to offer a new approach, founded on multiple mechanisms of action. That is why a part of researchers focused on psychoactive substances synthesized years ago and then banned. These days MDMA-assisted psychotherapy for the treatment of PTSD clinical trials are conducted, and due to previous results, the Food and Drug Administration (FDA) granted a breakthrough therapy designation. In this article, we present the mechanism of actions, the therapeutic rationale, applied psychotherapeutic methods, and potential dangers. If ongoing phase 3 studies are completed and clinical efficacy criteria are achieved, the FDA could approve the treatment as early as 2022.